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GLOBAL HEALTH RESEARCH HELPS SAVE LIVES   
Welcome to 2009’s third quarter Global 
Health E-Brief, designed to inform readers 
about key global health activities at the 
Centers for Disease Control and Preven-
tion (CDC). This issue highlights CDC’s 
global health research. Looking for 
ways to ensure efforts maximize health 
and economic impact, CDC conducts 
research to evaluate, compare, and 
improve health programs and policies 
at every stage — from initial planning 
and design through implementation 
under often-challenging field conditions 
in country. Research, particularly opera-
tions or applied research that takes sci-
ence from “laboratory to field” is one of 
CDC’s core contributions to the field of 
global health. 
Residents of the Field epidemiology Training Program in Thailand dissect bat samples during a 
leptospirosis outbreak investigation. operations research helps cDc understand the root cause of 
an outbreak and prevent additional illness.
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Asking the Right Questions Leads to Effective TB Treatment 
in People With HIV
CDC researchers have found that asking 
about the right combination of symp-
toms can be an effective tool to screen 
people with HIV for tuberculosis (TB). 
This relatively simple intervention is 
easily done in even the 
poorest, most resource-
limited settings. 
Hospital wards in 
Cambodia were once 
overwhelmed with 
people dying of AIDS. 
Today, with support 
from the President’s 
Emergency Plan for 
AIDS Relief (PEPFAR), 
Cambodian hospitals 
are seeing far fewer 
patients in such dire 
condition. Cambodians 
with HIV have better 
access to treatment and 
not only live longer, but 
are able to support their families. 
Unfortunately, misdiagnosis of TB, a com-
mon disease for people with HIV, threat-
ens many of the gains made by PEPFAR. 
TB is the most common cause of death for 
people with HIV. With early diagnosis and 
treatment, many of the deaths associated 
with TB could be prevented.
The World Health Organization (WHO) 
recommends that individuals with HIV 
be screened for TB when they are first 
diagnosed with HIV and periodically 
thereafter. Diagnosing TB in people 
with HIV can be difficult because they 
are more likely than persons who do not 
have HIV to have extra-pulmonary TB and 
to lack “classic” TB symptoms, such as 
chronic cough. In addition, the two most 
common tests for TB 
(chest x-ray and exami-
nation of sputum under 
a microscope) often fail 
to detect TB in people 
with HIV. One common 
approach, never studied 
for effectiveness, was 
to conduct further 
tests only if the person 
reports coughing for 2-3 
weeks. 
CDC, with financial 
support from the U.S. 
Agency for International 
Development (USAID) 
and PEPFAR, conducted 
a study to determine 
how best to screen for TB among people 
with HIV, even in the poorest, most 
resource-limited areas of the world. Work-
ing with local doctors and nurses, and 
the Ministries of Health in each country, 
CDC researchers enrolled 2,000 people 
with HIV in Cambodia, Vietnam, and 
Thailand. For each individual, scientists 
performed specialized TB tests—not 
usually available in countries with limited 
resources—to confirm the diagnosis of 
TB with as much certainty as possible. 
With this information, researchers then 
tested whether less resource-intensive 
methods, such as asking questions about 
specific symptoms, would be effective in 
diagnosing TB.
The results showed that 75% of TB diag-
noses were missed if people were asked 
only about whether they had a cough for 
at least 2 weeks. If health care workers 
asked about three specific symptoms 
(cough, fever, and night sweats), however, 
the percentage of TB diagnoses missed 
dropped to less than 10%.
Persons who reported having none of the 
three symptoms did not need additional 
tests and could be started safely on HIV 
treatment and TB prevention medication. 
Persons who reported one or more 
symptoms received additional tests. 
“We have known for a long time that TB 
screening is important in people with 
HIV, but we have not previously known 
how to do it. Now we have identified an 
Part of the study team at Sereysophon 
Referral Hospital in Banteay meanchey 
Province, cambodia, along with cDc staff. 
This site was the first to enroll patients 
in cambodia. The success of the study in 
achieving its goals is attributed to the hard 
work of staff at this and other hospitals that 
participated.
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“We have known for 
a long time that tB 
screening is important 
in people with HIV, but 
we have not previously 
known how to do it. 
Now we have identi-
fied an approach to 
accurately screen for 
this deadly disease 
even in very resource-
limited settings.”
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approach to accurately screen for this 
deadly disease even in very resource-
limited settings. This will not only have a 
dramatic impact on the life of individual 
patients, but also affect families and the 
population of small villages overall,” said 
Dr. Kevin Cain, a CDC expert on tubercu-
losis. “It was a heartwarming experience 
to be able to improve the diagnosis of 
these patients and give them a chance to 
recover from TB.”
These promising results have encour-
aged health officials in Cambodia, 
Vietnam, and Thailand to revise their 
national guidelines for TB screening and 
diagnosis in people with HIV. The revised 
national guidelines will end the use of 
chronic cough alone for TB screening, 
which misses too many patients with 
TB to be useful, and will replace it with 
screening based on multiple symptoms, 
such as those identified in this study. 
CDC is also working with the World 
Health Organization to incorporate these 
findings and other research into a new 
global policy on how people with HIV are 
screened for TB. 
CDC Research 
Looks at How to 
Make Rotavirus 
Vaccines More 
Effective in 
Developing 
Countries
“We in the developed countries often take 
vaccines and vaccination for granted, 
but children in many resource-poor, 
developing countries are still dying of 
vaccine-preventable diseases. That is the 
hardest and most important lesson I have 
learned.” 
—Dr. Baoming Jiang
(WHO), Program for Appropriate Tech-
nology in Health (PATH), United Nations 
Children’s Fund (UNICEF), the Bill and 
Melinda Gates Foundation, and the 
Global Alliance for Vaccines and Immuni-
zations, Jiang and vaccine manufacturers 
in China, India, and Vietnam are working 
to better understand the reasons for the 
reduced effectiveness and how to modify 
the vaccines so that they are effective. 
CDC is also collaborating with partners 
to develop a needle-less micro-patch to 
deliver rotavirus vaccine. This technology 
may make it easier to vaccinate large 
populations during immunization cam-
paigns. All of these efforts are essential 
for progress in developing improved 
vaccines that protect 
children against local 
strains of rotavirus, 
and are less expensive 
and therefore more 
available to those who 
need them most.  
Jiang has been involved 
in the development of 
rotavirus vaccines for 
children in developed 
and developing 
countries for more than 
17 years. For Jiang, 
vaccine research is “a 
noble profession that saves hundreds of 
thousands of lives each year.” His con-
tributions to vaccine development were 
recently recognized in the journal Nature 
Reviews Drug Discovery (www.nature.com/
nrd/journal/v7/n5/full/nrd2587.html). 
Thanks to the efforts of CDC research 
microbiologist Baoming Jiang and col-
leagues, the day is coming when develop-
ing countries will have vaccines effective 
against indigenous strains of rotavirus.
Rotavirus is the leading cause of severe 
diarrheal disease in children worldwide 
and causes the deaths of nearly 1,400 
children each day in developing countries. 
The severe dehydration caused by 
rotavirus is easily treated in the United 
States and other developed countries, but 
an effective vaccine is the key to saving 
lives in the developing world. 
Two oral rotavirus vaccines available 
since 2006 have been shown to be 
effective in developed 
countries in the 
Americas, Europe, 
and Australia, but 
they have been less 
effective in preventing 
hospitalizations and 
deaths from rotavirus 
disease in developing 
countries. Possible 
reasons include the 
presence of other 
enteric infections and 
persistent levels of 
malnutrition. Further-
more, many develop-
ing countries don’t have the technology 
and resources needed to make and use 
the oral vaccines.
Supported by an array of partners, 
including the World Health Organization 
cDc’s Dr Baoming Jiang 
(sitting) conducts an 
in-country consultation 
in Vietnam with 
representatives of PolyVac, 
a vaccine manufacturer in 
Hanoi, Vietnam. 
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“We in the developed coun-
tries often take vaccines and 
vaccination for granted, but 
children in many resource-
poor, developing countries 
are still dying of vaccine- 
preventable diseases. that is 
the hardest and most impor-
tant lesson I have learned.” 
— dr. Baoming Jiang
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CDC has joined a cadre of partners to 
reduce the risk of respiratory infections 
and pneumonia in children in rural 
western Kenya. Village by village, CDC, 
the World Health Organization (WHO) 
and Kenyan partners are showing how 
the use of a simple and relatively low-
cost intervention clean-burning cook 
stoves – can help prevent pneumonia 
and improve health and economies in 
sub-Saharan Africa.
Few know that pneumonia kills ap-
proximately 2 million children under 
the age of five years, worldwide each 
year. Resource-poor countries are 
particularly hard hit—for every child 
who dies of pneumonia in a developed 
country, more than 2,000 children die of 
pneumonia in developing countries. 
WHO reports that indoor smoke from 
solid fuels is 10th on a list of 26 risk 
factors contributing to the global 
burden of all disease. Indoor smoke 
released from fuels used to cook and 
boil drinking water is the main risk 
factor for one-third of pneumonia 
infections. The problem is particularly 
evident in sub-Saharan Africa where 
1 in 3 young children are reported to 
have pneumonia each year and up to a 
third of pneumonia deaths are at-
tributed to indoor smoke released from 
fuels used during cooking.  
In the villages of rural western Kenya, 
traditional open fire pits are used in 
homes for cooking and 
heating. As is tradition, 
women often keep their 
young children nearby 
while cooking, and fam-
ily members sometimes 
sleep in cooking rooms 
which may not vented 
to the outdoors. As a 
result, all breathe in 
particulate matter—
carbon monoxide, 
greenhouse gases, 
and other pollutants. 
A 2007 survey CDC 
conducted in Kenya’s Nyanza Province 
found a heavy burden associated with 
respiratory diseases. Parents reported 
that nearly a quarter (22%) of children 
younger than age 3 had experienced 
an acute respiratory infection in the 
previous 24 hours. 
To address the problem, CDC partnered 
with WHO, the Kenya Ministry of 
Health, the Safe Water and AIDS Project 
(a Kenyan non-governmental organiza-
tion), and GTZ (a private international 
enterprise that works with the German 
government to improve people’s living 
conditions on a sustainable basis) to 
encourage the use of locally crafted 
low-cost, clean-burning stoves (Jiko 
Kisasa stoves) in 10 Kenyan villages. 
Unlike the traditional fire pits, the 
clean-burning stoves contain the fire 
and help to prevent 
release of particulate 
matter into the air. 
CDC scientists collect-
ed data in the project’s 
10 villages to learn 
more about health and 
spending priorities and 
how social networks 
can spread the word 
about new technologies 
in resource-limited set-
tings. Researchers used 
Google Maps to plot 
where stoves are bought and installed. 
Particulate monitors in homes track 
changes in the air quality after installa-
tion and use of the stoves. Researchers 
interviewed members of more than 
1,000 households in 59 villages. Pneu-
monia was reported as the second most 
commonly reported health problem 
among children, and cooking fuel was 
the sixth most common expenditure of 
households. 
Kenyans in homes using the stoves 
reported fewer respiratory illnesses. 
The project has had economic benefits 
as well. Project organizers have helped 
financially vulnerable women use their 
social networks to promote and sell 
the stoves—creating a new source of 
income for these women. Stoves cost 
about US$3-4 and require less fuel than 
open fire pits, enabling families to use 
their limited income for other needs, 
including healthcare and education. 
Rates of acute 
respiratory infections 
in children are high in 
Kenya. mothers typically 
have their babies and 
young children with 
them while cooking and 
many also sleep in the 
cooking room.
Not Just Blowing Smoke: Simple, Low-
Cost Changes Reduce Respiratory 
Disease in Kenyan Children
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One villager praised her 
new stove: “I no longer 
have concern about my 
children’s health while 
cooking with the new Jiko 
stove. It produces less 
smoke so my children will 
not be sick, and it cannot 
burn my children.” 
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One villager praised her new stove: “I no 
longer have concern about my children’s 
health while cooking with the new Jiko 
stove. It produces less smoke so my 
children will not be sick, and it cannot 
burn my children.”
The project continues to scale up with a 
goal to reach families in 50 more villages 
in rural western Kenya within the year. 
Monitoring of respiratory disease in this 
region will continue, along with collec-
tion and evaluation of data on presence 
of particulate matter in households with 
properly installed cooking stoves. This in-
formation will inform the effectiveness of 
the program and help to prioritize future 
sites. CDC and the other implementing 
partners are also collecting information 
about consumer use and satisfaction 
with the clean-burning stoves and testing 
social marketing approaches in different 
villages to ensure that lessons learned 
and best practices are incorporated as 
the project expands. 
CDC Costing 
Study Helps Ensure 
Sustainability of 
Global HIV Care 
and Treatment 
Programs
Over the past five years, more than 
2.1 million men, women, and children 
around the world have received life-
saving treatment for HIV with support 
from the U.S. President’s Emergency Plan 
for AIDS Relief (PEPFAR) program. Every 
month, PEPFAR helps provide access to 
HIV treatment for 60,000 new people who 
would otherwise have few or no options 
for addressing their HIV disease. One of 
the most important treatment options in 
the battle against HIV/AIDS has been the 
use of antiretroviral therapy (ART)—the 
use of at least three antiretroviral (ARV) 
drugs to stop the progression of disease. 
As a key implementing agency in PEPFAR, 
CDC leads the coordination of PEPFAR’s 
applied (or operations) and effectiveness 
research, which measures the outcomes 
and impact of PEPFAR interventions to 
inform future program design and to 
ensure efficient use of resources. 
Today, CDC is leading an advanced 
economic evaluation of HIV treatment 
throughout PEPFAR countries. This type of 
evaluation will help countries and donors 
plan and use resources effectively to 
continue to improve and maintain these 
HIV treatment programs over many years. 
In 2006, when new HIV treatment 
programs were being scaled-up 
across Africa, CDC developed the 
first multi-country ART costing study 
for PEPFAR, which assessed ART 
program costs in more than 45 health 
facilities in Nigeria, Ethiopia, Uganda, 
Botswana, and Vietnam. Findings 
from the study provided a breakdown 
of the major costs associated with 
new ART programs and the average 
annual per-patient treatment cost 
across multiple agencies, partners, and 
facilities. This effort allowed Ministries 
of Health and PEPFAR country teams to 
project treatment costs under different 
funding and care scenarios, leading to 
more strategic decisions that help to 
ensure long-term sustainability of the 
treatment programs in these countries.  
PEPFAR is now expanding this effort to 
conduct a PEPFAR-wide ART costing 
initiative, which includes:
reviewing each PEPFAR country team’s •	
understanding of the economic and 
clinical aspects of its ART program; 
sharing sophisticated methods for •	
determining the comprehensive costs 
of the treatment programs; and 
helping country teams to use costing •	
information and modeling to determine 
the capacity of the PEPFAR program 
and countries to maintain ART for 
individuals who are currently receiving 
treatment, and to enroll new patients. 
This baby is receiving ART; evaluating the cost effectiveness of ART 
programs in Africa and elsewhere in the world will help make the 
programs stronger saving future generations like this baby. 
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Now more than ever, 
country programs need 
robust data on treatment 
costs—and ultimately care 
and prevention program 
costs—to continue treat-
ment scale-up and maintain 
balanced programs. 
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“Because of the recent global economic 
downturn, understanding the cost of 
ART is critical”, says Dr. John Blandford, 
a senior CDC health economist and 
principal investigator of the study. 
“Ministries of Health are facing severe 
budget constraints and donor resources 
have flattened. Now more than ever, 
country programs need robust data on 
treatment costs—and ultimately care 
and prevention program costs—to 
continue treatment scale-up and 
maintain balanced programs.” 
The advanced economic analysis takes 
into account some of the issues faced 
by treatment programs as they mature, 
including decreasing costs for existing 
antiretroviral drugs, introduction of 
newer, better therapies into the market 
at a higher price, and the need to move 
people over time to more expensive 
second-line regimens as resistance to 
first-line drugs develops.  
Once final data are available, countries 
can estimate their total treatment costs 
and major cost drivers of ART under 
different scale-up scenarios, such as 
meeting the goal of universal access 
to ART. In so doing, countries can 
anticipate future resource needs and 
leverage additional donor support, such 
as from the Global Fund to Fight HIV/
AIDS, TB, and Malaria. Furthermore, the 
cost projection information will help 
shape PEPFAR Partnership Frameworks, 
the 5-year strategic frameworks for 
cooperation between U.S. and host 
partner governments focused on 
securing long-term sustainability of HIV/
AIDS programs.
In 2009, CDC is supporting 124 country-
specific program evaluations and six 
multi-country public health evalua-
tions, the latter which will answer key 
program-wide questions on preventing 
mother-to-child transmission of HIV, 
tuberculosis, health systems strengthen-
ing, and HIV counseling and testing. 
With Findings from 
CDC Research, 
Africans Use Rapid 
Diagnostic Tests 
to Effectively Treat 
Malaria
CDC research is helping to find the best 
ways to use new rapid diagnostic tests 
in Africa to help save lives and scarce 
resources.
Rapid, accurate diagnosis of malaria 
historically has been difficult. Until 
recently, the only way to diagnose the 
disease was for a skilled laboratory 
worker to use a microscope to look for 
malaria parasites in a blood sample. 
Unfortunately, many facilities had 
neither the microscope nor adequately 
skilled staff. So a mother who brought 
her ill child to a clinic in sub-Saharan 
Africa with symptoms of fever and 
headache often was simply given 
antimalarial medication. There were two 
problems with that approach: the child 
might not have malaria and wouldn’t 
improve, and overuse of antima-
larial drugs can lead to drug resistance, 
causing the currently useful drugs to 
become ineffective. 
Availability of rapid diagnostic tests 
(RDTs) has allowed health workers to 
determine in as little as 15 minutes 
whether a patient has malaria. As a 
result, workers can treat children and 
adults with effective antimalarial drugs 
or look further for the cause of illness. 
Ultimately, the result is fewer complica-
tions and deaths.
Many malaria-endemic countries have 
started to use RDTs, and CDC has 
collaborated with local research institu-
tions in Kenya and Tanzania to learn 
more about how best to use these tests 
in routine patient care. Although rapid, 
the tests are not necessarily simple to 
perform, require storage at the right 
temperature and humidity, and produce 
results that are not always accepted by 
health workers, largely because older 
guidelines from WHO called for treat-
ment without diagnosis, a lack of 
experience in using RDTs, and changing 
national malaria treatment guidelines. 
Health worker in 
Tanzania performing 
a rapid diagnostic 
test for malaria.
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S. Patrick Kachur, CdC
availability of rapid diagnostic 
tests (rdts) has allowed health 
workers to determine in as 
little as 15 minutes whether a 
patient has malaria. 
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Recent studies showed that after the new 
tests were introduced, health workers 
needed training to use the tests appropri-
ately. A CDC study in rural Tanzania found 
that, despite training and supervision, 
some health workers did not perform 
the tests correctly or use the results to 
influence treatment decisions. Another 
study in Kenya showed that use of RDTs 
did not improve treatment of malaria 
cases. Instead of increasing the number 
of people tested at a clinic, fewer people 
with malaria symptoms were tested. Both 
studies signaled the need to understand 
more about why health workers were not 
using RDTs and how best to encourage 
their appropriate use. 
Recent research conducted in 2008 by 
CDC scientists in Tanzania has found that 
health workers at outlying health facilities 
successfully use RDTs to improve care 
when they receive appropriate supervision 
and RDT quality control procedures 
are followed. As a result, the Tanzanian 
National Malaria Control Program will take 
steps to improve supervision and quality 
control of malaria RDTs nationwide.
With the proper supports in place in 
health facilities, public health officials 
are encouraged that the use of RDTs will 
improve diagnosis of malaria and effective 
treatment for individuals – another step 
forward in the battle against malaria.
Dr. Larry Slutsker, who leads CDC’s malaria 
program, is pleased with the progress in 
effective use of the rapid tests.
“We need to have accurate malaria 
diagnosis—for better case management 
of sick people and to track our progress in 
controlling this disease. RDTs will play an 
important role in these efforts.” Malaria 
causes approximately 500 million infec-
tions and more than one million deaths 
annually; most deaths occur in young 
children. Although about one-half of the 
world’s population is at risk for malaria, 
90% of the cases and deaths occur in 
sub-Saharan Africa. 
A recent CDC-led intervention to improve 
routine immunization coverage in 
the state of Assam, India, resulted in 
vaccination of 12,000 children to prevent 
infectious diseases–a 29% increase in 
coverage in one district.
Assam is famous for its tea estates and 
rich in natural resources and culture, yet 
still lacks basic infrastructure to effective-
ly deliver healthcare, including routine 
immunizations for children. Immuniza-
tions are critical to reducing morbidity 
and mortality caused by diseases such as 
measles, polio and tetanus.
The major barriers to routine immuniza-
tion are common throughout India: 
lack of trained health care workers and 
supervisors, shortages of vaccine, and 
power outages that render vaccines 
ineffective when refrigeration fails. For 
these reasons, each year an estimated  
9.7 million Indian children are only par-
tially vaccinated by the age of one year, 
and remain vulnerable to disability and 
death from serious infectious diseases.
To improve routine immunization coverage, 
CDC partnered with United Nations Chil-
dren’s Fund (UNICEF) and the government 
of Assam to implement and evaluate the 
effectiveness of the Reaching Every District 
(RED) intervention. The project trained 
program staff from eight districts in Assam 
in the essential elements of a successful 
immunization campaign:
Supportive supervision•	
Outreach vaccination sessions •	
Strong links with communities•	
Planning and management of resources•	
Monitoring for action•	
cDc Public Health Advisor Tove Ryman presents at a ReD training 
in Assam, India.
Photo by: 
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Improved Routine Immunization Means 
More Children Protected from Disease 
in Assam, India
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Two of the eight districts were selected as 
focus districts, and each was supported 
by a full-time UNICEF consultant. CDC 
public health advisor Tove Ryman helped 
establish the project and visited each 
focus district to launch the intervention. 
During the year-long intervention CDC 
conducted quarterly site visits. 
One year after implementation, the 
results are exciting and promising. The 
number of fully vaccinated children 
increased in every district that received 
the RED intervention. In Barpeta, one 
of the focus districts, the percentage 
of children vaccinated increased by 
29 percent among children ages 12-23 
months. Barpeta also had improvements 
in program record-keeping and recording, 
calculating and interpreting information, 
frequency of supervision, and increased 
numbers of outreach sessions and links 
with communities.  
One immunization worker in the district 
described the impact of the intervention 
this way: “Now we can calculate our 
coverage and also find dropouts. And 
we communicate better with people 
than before.”
Ryman noted that “For the first time, we 
established a baseline so that we can 
most effectively measure the impact 
of the RED strategy.” She adds, “It was 
really rewarding to see the quality of 
the program enhanced as a result of the 
intervention.”
The lessons learned in Assam are now 
being put into practice by CDC and 
partners in the populous Indian states 
of Jharkhand and Bihar. One finding 
was that many of the staff delivering 
immunization services had not received 
any job-related training. Trainers now 
conduct skill-building exercises at a 
very basic level. CDC and UNICEF also 
learned that training was more effective 
when broken into modules taught over 
time, rather than in one long session. 
Now, trainees practice new skills and 
then review them with trainers. 
“For the first time, we 
established a baseline so 
that we can most effectively 
measure the impact of the 
red strategy.”
WHO: Elimination of River 
Blindness Possible in Africa
Results of a World Health Organization 
study published in the open-access 
journal PLoS Neglected Tropical Diseases 
presents the first evidence that treatment 
with ivermectin may help the world 
eliminate onchocerciasis (river blindness).
Mass ivermectin treatment has been 
widely accepted as a proven strategy to 
control the disease and, in Latin America, 
ivermectin twice-annual treatments have 
interrupted transmission in a number of 
areas. Until now, however, there has been 
no evidence in Africa that ivermectin could 
interrupt transmission of the parasite and 
eliminate the disease in endemic areas. 
The WHO study showed that after 15-17 
years of annual treatments, only a few 
infections remained in humans. Because 
transmission levels were below the thresh-
old required for elimination, treatment 
was stopped in test areas; follow-up evalu-
ations after 1.5 to 2 years found no further 
infections or transmission. The authors 
report that the findings are evidence, in 
principle, that onchocerciasis elimination 
is feasible in Africa. Further studies are 
necessary to determine whether transmis-
sion recurs and under what circumstances.
To view the news release visit WHO:  
www.who.int/mediacentre/news/
releases/2009/river_blindness_ 
20090721/en/index.html
To view the study visit PLoS Neglected 
Tropical Diseases: 
www.plosntds.org/article/ 
info%3Adoi%2F10.1371%2F 
journal.pntd.0000497
CDC Assigns Epidemiologist 
to WHO China for Assistance 
to Eradicate Hepatitis B Virus
With support from the ZeShan Founda-
tion, a family foundation concerned with 
the prevention and treatment of HIV/
AIDS and Hepatitis B, CDC has assigned 
Dr. Yvan Hutin to the World Health 
Organization (WHO) China Office. Hutin 
will work with China and other countries 
in WHO’s Western Pacific Regional Office 
to reduce early childhood hepatitis B 
virus (HBV) infections from more than 8% 
to less than 2% by 2012. HBV deaths in 
the region, primarily from cirrhosis and 
liver cancer caused by chronic infection 
acquired at birth, account for more 
than 50% of the world’s HBV deaths.
CDC Supports Preventing 
Violence against Children 
Study in Tanzania, Zanzibar 
Violence against children is an urgent public 
health issue in Tanzania. Reports indicate that 
31% of girls and 25% of boys in Tanzania have 
experienced at least one incidence of sexual 
violence before the age of 18
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At the request of the United Nations 
Children’s Fund (UNICEF), CDC is 
providing technical assistance to conduct 
a national survey on violence against 
children in Tanzania and Zanzibar. Data 
from the survey will be used to identify the 
national prevalence of violence against 
children in Tanzania and Zanzibar; risk 
and protective factors for victimization; 
and health outcomes of such violence. 
Findings from the survey will be used to 
inform policy and program development 
on the prevention of violence against 
children. The CDC team will begin 
interviewer training and data collection 
in the two countries in October 2009.
For more information, visit Global 
Violence Prevention at: 
www.cdc.gov/ViolencePrevention/
globalviolence/index.html
November 2, 2009, is  
World Pneumonia Day
Major health and humanitarian relief 
organizations are joining forces to coordi-
nate education outreach, walks, runs and 
policy summits in New York, Washington 
DC, Kenya, Nigeria, India and Bangladesh 
on November 2nd to increase awareness 
that preventing pneumonia saves lives.
For more information, visit:  
www.WorldPneumoniaDay.org
Learn more about pneumonia in a special 
Notice to Readers in the November 2nd, 
2009 issue of the Morbidity and Mortality 
Weekly Report (MMWR) at: 
www.cdc.gov/mmwr
Burma Ministry of Health 
Launches the DOTS PLUS 
Program for Management 
of Multidrug-Resistant 
Tuberculosis 
The Ministry of Health of Burma recently 
launched the DOTS PLUS for Multidrug-
Resistant Tuberculosis Management 
Program. DOTS PLUS is the internation-
ally recommended strategy for treating 
drug-resistant tuberculosis that builds 
upon the standard program for treating 
drug-sensitive tuberculosis—DOTS 
(Directly observed therapy, short-course). 
The launch was made possible by the col-
laboration and support of multiple private 
and public partners and donors, including 
the World Health Organization (WHO), 
United States Agency for International 
Development (USAID), United Nations 
Children’s Fund (UNICEF), and others. 
CDC employees who helped advance the 
collaboration included Dr. John MacArthur, 
on detail to USAID’s Regional Develop-
ment Mission in Asia, who oversaw 
USAID’s participation in this collaboration, 
and Dr. Jay Varma, who provided technical 
assistance to USAID and the U.S. Embassy 
in Burma on assessment and implementa-
tion. The first patients enrolled in the 
program began receiving treatment in July.
For more information visit WHO TB: 
www.who.int/tb/dots/en
CDC Helps Advance Public 
Health Management and 
Leadership in Ghana 
CDC provided technical assistance to help 
launch the Centre for Leadership and 
Management at the University of Ghana 
School of Public Health. CDC collaborated 
with University of Ghana School of Public 
Health to develop a detailed curriculum, 
lesson plan, course schedule, and instruc-
tion for the Centre’s four-week course 
entitled “Improving Management of Public 
Health Interventions.” Twenty-two public 
health professionals from Ghana, Kenya, 
Tanzania and Uganda attended the course 
held at the University of Ghana School 
of Public Health June 22-July 17. Faculty 
members included representatives from 
the World Health Organization (WHO), 
African Field Epidemiology Network 
(AFENET), Field Epidemiology and 
Laboratory Training Program (FELTP), the 
Ghana Health Service, the Ghana School 
of Public Health and CDC. The Ghana 
Health Service has now adopted the 
program for senior leadership training.
For every 1 child that dies of pneumonia in an 
industrialized country, more than 2000 children 
die of pneumonia in developing countries.  
World Pneumonia Day on November 2nd will 
bring worldwide awareness of this disease so 
that it may be eradicated one day.
Dr. John macArthur (USAID, on detail from US 
cDc), and Dr. Hans Kluge, medical officer-
TB, (WHo/Burma) see the first patient receive 
TB medications as part of the DoTS PlUS 
program.
managers of health districts and hospitals in 
Ghana, Kenya, Tanzania and Uganda partici-
pate in the Project management workshop, 
facilitated by cDc Training Specialist Denise 
Traicoff.
